IP Library › Granted Patent US 12,258,390
Granted Patent B2
US 12,258,390 · App. 18/160,355 · Granted Mar 25, 2025

Methods and agents for the treatment of ocular disease

Inventors: Brian W. Ziegelaar (Brisbane, AU); Garry L. Redlich (Brisbane, AU)
Assignee: Line 6 Biotechnology, Inc.
C07K16/22C07K16/468C07K16/28C07K2317/565C07K2317/567
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,258,390
App. No.
18/160,355
Granted
Mar 25, 2025
Kind
B2
Abstract

This disclosure relates generally to methods and agents for treating an ocular disease or disorder. More particularly, the present disclosure relates to the use of CD14 antagonist antibodies for treating an ocular disease or disorder.

Claims (20)

1. A method for reducing ocular fibrosis in a subject with wet age-related macular degeneration (AMD) and ocular fibrosis, comprising administering to the eye of the subject an amount of a CD14 antagonist antibody, or antigen binding fragment thereof, effective to reduce ocular fibrosis in the subject, wherein the CD14 antagonist antibody, or antigen binding fragment thereof, is either administered alone or in combination with an anti-VEGF agent.

2. The method of claim 1 , wherein the CD14 antagonist antibody, or antigen binding fragment thereof, comprises:

a) an antibody VL domain comprising L-CDR1, L-CDR2 and L-CDR3, wherein L-CDR1 comprises the sequence RASESVDSYVNSFLH [SEQ ID NO: 13], L-CDR2 comprises the sequence RASNLQS [SEQ ID NO: 14], and L-CDR3 comprises the sequence QQSNEDPYT [SEQ ID NO: 27]; and

b) an antibody VH domain comprising H-CDR1, H-CDR2 and H-CDR3, wherein H-CDR1 comprises the sequence SDSAWN [SEQ ID NO: 16], H-CDR2 comprises the sequence YISYSGSTSYNPSLKS [SEQ ID NO: 17], and H-CDR3 comprises the sequence GLRFAY [SEQ ID NO: 18].

3. The method of claim 1 , wherein the CD14 antagonist antibody, or antigen binding fragment thereof, is of the IgG1 isotype.

4. The method of claim 1 , wherein the CD14 antagonist antibody, or antigen binding fragment thereof, is of the IgG1 isotype and comprises L234A and L235A mutations.

5. The method of claim 1 , wherein the CD14 antagonist antibody, or antigen binding fragment thereof, is a chimeric, humanized or human antibody.

6. The method of claim 1 , wherein the subject has received an anti-VEGF agent for at least 3, 6, 9, 12, 14, 16 or 18 months.

7. The method of claim 6 , wherein the anti-VEGF agent is selected from the group consisting of an anti-VEGF antibody, anti-VEGF antibody mimetic, VEGF Trap molecule, soluble fms-like tyrosine kinase-1, and a tyrosine kinase inhibitor.

8. The method of claim 7 , wherein the anti-VEGF antibody is selected from the group consisting of brolicizumab, ranibizumab and faricimab.

9. The method of claim 7 , wherein the VEGF Trap molecule is aflibercept or conbercept.

10. The method of claim 7 , wherein the anti-VEGF antibody mimetic is abicipar pegol.

11. The method of claim 7 , wherein the tyrosine kinase inhibitor is a Tie2 inhibitor or an Ang-2 inhibitor.

12. The method of claim 1 , wherein the CD14 antagonist antibody, or antigen binding fragment thereof, is administered in combination with an anti-VEGF agent.

13. The method of claim 12 , wherein the anti-VEGF agent is selected from the group consisting of an anti-VEGF antibody, anti-VEGF antibody mimetic, VEGF Trap molecule, soluble fms-like tyrosine kinase-1, and a tyrosine kinase inhibitor.

14. The method of claim 13 , wherein the anti-VEGF antibody is selected from the group consisting of brolicizumab, ranibizumab and faricimab.

15. The method of claim 13 , wherein the VEGF Trap molecule is aflibercept or conbercept.

16. The method of claim 13 , wherein the VEGF antibody mimetic is abicipar pegol.

17. The method of claim 13 , wherein the tyrosine kinase inhibitor is a Tie2 inhibitor or an Ang-2 inhibitor.

18. The method of claim 12 , wherein the subject has received an anti-VEGF agent for at least 3, 6, 9, 12, 14, 16 or 18 months.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2023
From: ZIEGELAAR, BRIAN W.; REDLICH, GARRY L.
To: LINE 6 BIOTECHNOLOGY, INC.
Reel/Frame 062712/0947 →
Priority Claims (1)
AU 2020903624 · Oct 7, 2020 · national
Continuity (3)
Continuation 17678861 · Feb 23, 2022
Continuation PCTAU2021051173 · Oct 7, 2021
Related Publication 20240002489A1 · Jan 4, 2024
References Cited (63)
US 5820858A · Leturcq et al. · 1998 [cited by applicant]
US 6444206B1 · Leturcq et al. · 2002 [cited by applicant]
US 7326569B2 · Leturcq et al. · 2008 [cited by applicant]
US 10407510B2 · Kelley et al. · 2019 [cited by applicant]
US 11618782B2 · Ziegelaar et al. · 2023 [cited by applicant]
US 20060121574A1 · Allison · 2006 [cited by applicant]
US 20150126458A1 · Hohman et al. · 2015 [cited by applicant]
US 20160319002A1 · Patel · 2016 [cited by applicant]
US 20160038589A1 · Sennlaub et al. · 2016 [cited by applicant]
US 20160340424A1 · Bansal · 2016 [cited by applicant]
US 20220220194A1 · Ziegelaar et al. · 2022 [cited by applicant]
KR 1020190059164A · 2019 [cited by applicant]
WO WO200242333A1 · 2002 [cited by applicant]
WO WO2006121871A2 · 2006 [cited by applicant]
WO WO2009002790A2 · 2008 [cited by applicant]
WO WO2009089401A2 · 2009 [cited by applicant]
WO WO2015110556A1 · 2015 [cited by applicant]
WO WO2018191786A1 · 2018 [cited by applicant]
WO WO2022073072A1 · 2022 [cited by applicant]
International Search Report and Written Opinion of the International Searching Authority for International Application No. PCT/AU2021/051173, dated Nov. 11, 2021, 8 pages. [cited by applicant]
Adachi et al., “Inhibition by a CD14 monoclonal antibody of lipopolysaccharide binding to murine macrophages,” J. Endotoxin Res., 1999, 5(3): 139-146. [cited by applicant]
Ahn et al., “Subretinal fibrosis after antivascular endothelial growth factor therapy in eyes with myopic choroidal neovascularization,” Retina, 2016, 36(11): 2140-2149. [cited by applicant]
Alsalamah et al., “Recognizable Patterns of Submacular Fibrosis in Enhanced S-Cone Syndrome,” Opthalmol Retina, 2021, 5(9): 918-927. [cited by applicant]
Axtelle et al., “IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis,” J. Endotoxin Res., 2001, 7(4): 310-314. [cited by applicant]
Bazil et al., “Biochemical characterization of a soluble form of the 53-kDa monocyte surface antigen,” Eur. J. Immunol., 1986, 16(12): 1583-1589. [cited by applicant]
Cetin et al., “Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections,” Graefe's Archive for Clinical and Experime… [cited by applicant]
Cogan et al., “Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides,” Investigative Opthalmology & Visual Science, May 2017, 58(5): 2578-2590. [cited by applicant]
Daniel et al., “Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials,” Opthalmology, Mar. 2014, 121(3): 656-666. [cited by applicant]
Daniel et al., “Development and Course of Scars in the Comparison of Age-related Macular Degenerations Treatments Trials (CATT),” Opthalmology, Jul. 2018, 125(7): 1037-1046. [cited by applicant]
Droho et al., “Monocyte-Derived Macrophages Are Necessary for Beta-Adrenergic Receptor-Driven Choroidal Neovascularization Inhibition,” Invest Ophthalmol Vis Sci, Dec. 2019, 60(15): 5059-5069. [cited by applicant]
Enriquez et al., “Update on Anti-Vascular Endothelial Growth Factor Safety for Retinopathy of Prematurity,” Asia-Pacific Journal of Opthalmology, Aug. 2020, 9(4): 358-368. [cited by applicant]
Funk et al., “Angiogenic and Inflammatory Markers in the Intraocular Fluid of Eyes With Diabetic Macular Edema and Influence of Therapy With Bevacizumab,” Retina, 2010, 30(9): 1412-1419. [cited by applicant]
Gao et al., “A serum metabolomics study of patients with nAMD in response to anti-VEGF therapy,” Scientific Reports, 2020, 10:1341, 10 pages. [cited by applicant]
Golzarri et al., “Risk factors for subretinal fibrosis in patients with Vogt Koyanagi Harada syndrome,” Ocul Immunol Inflamm Oct. 2020, 6:1-5. [cited by applicant]
Hu et al., “Recurrence of Retinopathy of Prematurity in Zone II Stage 3+ after Ranibizumab Treatment: A Retrospective Study,” J Ophthalmol, 2017, Article ID 5078565, pp. 1-5. [cited by applicant]
Idrees et al., “Proliferative Vitreoretinopathy: A Review,” Int. Opthalmol Clin., 2019, 59(1): 221-240. [cited by applicant]
Ishikawa et al., “Molecular mechanisms of subretinal fibrosis in age-related macular generation,” Experimental Eye Research, vol. 142, Mar. 15, 2015, pp. 19-25. [cited by applicant]
Juan et al., “Identification of a Lipopolysaccharide Binding Domain in CD14 between Amino Acids 57 and 64,” J. Biol. Chem., Mar. 1995, 270(10): 5219-5224. [cited by applicant]
Juan et al., “Identification of a Domain in Soluble CD14 Essential for Lipopolysaccharide (LPS) Signaling but Not LPS Binding,” J. Biol. Chem., Jul. 1995, 270(29): 17237-17242. [cited by applicant]
Khojasteh et al., “Autosomal Recessive Bestrophinopathy: Clinical and Genetic Characteristics of Twenty-Four Cases,” J. Opthalmol, Apr. 2021, Article ID 6674290, 11 pages. [cited by applicant]
Lau et al., “Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation,” The Journal of Immunology, Sep. 2013, 191: 4769-4777. [cited by applicant]
Lee et al., “Association Between Soluble CD14, in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema,” Investigative Ophthalmology & Visual Science, vol. 5… [cited by applicant]
Leturcq et al., “Antibodies against CD14 protect primates from endotoxininduced shock.” J. Clin. Invest., Oct. 1996, 98(7): 1533-1538. [cited by applicant]
Li et al., “Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab,” Int J Ophthalmol, Dec. 2015, 8(6): 1202-1206. [cited by applicant]
Mandal et al., “Ocular delivery of proteins and peptides: Challenges and novel formulation approaches,” Advanced Drug Delivery Reviews, Jan. 2018, vol. 126: 67-95. [cited by applicant]
Marano et al., “Hereditary retinal dystrophies and choroidal neovascularization,” Graefe's Arch Cln Exp Opthalmol, 2000, 238: 760-764. [cited by applicant]
Murakami et al., “Innate immune response in retinal homeostasis and inflammatory disorders.” Progress in Retinal and Eye Research, 2020, 74: 100778. [cited by applicant]
Osaadon, “A review of anti-VEGF agents for proliferative diabetic retinopathy,” Eye (Lond), Feb. 2014, 28(5): 510-520. [cited by applicant]
Roy et al., “Retinal Fibrosis in Diabetic Retinopathy,” Experimental Eye Research, Jan. 2016, 142: 71-75. [cited by applicant]
Schlunck et al., “Conjunctival fibrosis following filtering glaucoma surgery,” Exp. Eye Res., 2016, 142: 76-82. [cited by applicant]
Sen et al., “Coats disease: An overview of classification, management and outcomes,” Indian J. Opthalmol, 2019, 67(6): 763-771. [cited by applicant]
Shen et al., “Construction and Expression of a Novel Anti-CD14 Human-Mouse Chimeric Antibody Hm2F9,” DNA Cel Biol., 2014, 33(9): 599-604. [cited by applicant]
Tang et al., “Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells,” Immunopharmacol Immunotoxicol, 2007, 29: 375-386. [cited by applicant]
Tarib et al., “An Atypical Idiopathic Retinal Vasculitis, Aneurysms and Neuroretinitis IRVAN: Case Report,” J Clin Exp Ophthal, Feb. 2020, vol. 11, Issue 1, No. 1000824, 4 pages. [cited by applicant]
Tasaka et al., “Effect of CD14 Blockade on Endotoxin-Induced Acute Lung Injury in Mice,” Am. J. Respir. Cell. Mol. Biol., 2003, 29(2): 252-258. [cited by applicant]
Tong et al., “Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab,” BMC Ophthalmology, Jun. 2018, 18:150, 9 pages. [cited by applicant]
Tsutsumi et al., “The critical role of ocular-infiltrating macrophages in the development of choroidal neovascularization,” J Leukoc Biol, Jul. 2003, 74(1): 25-32. [cited by applicant]
Van Voohris et al., “Specific Antimononuclear Phagocyte Monoclonal Antibodies,” J. Exp. Med., Jul. 1983, 158: 126-145. [cited by applicant]
Xiao et al., “Risk factors for subretinal fibrosis after anti-VEGF treatment of myopic choroidal neovascularisation,” Br J Ophthalmol, 2020, 6 pages. [cited by applicant]
Zhavoronkov et al., “Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma,” Cell Cycle, 2016, 15(12): 1643-1652. [cited by applicant]
Zhu et al., “Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathological myopia (Review),” Cochrane Database of Systematic Reviews, 2016, Issue 12, Art No. CD011160, 56 pages. [cited by applicant]
Levy et al., “Apolipoprotein E promotes subretinal mononuclear phagocyte survival and chronic inflammation in age-related macular degeneration,” EMBO Molecular Medicine, vol. 7, No. 2, Jan. 20, 2015, pp. 211-226. [cited by applicant]
Umazume et al., “Effects of Soluble CD14 and Cytokine Levels on Diabetic Macular Edema and Visual Acuity,” Retina, The Journal of Retinal and Vitreous Diseases, vol. 33, No. 5 2013, pp. 1020-1025. [cited by applicant]